Skip to content
Recovery & Performance PeptidesRecovery research and practical context
Source comparison

Peptides for Endurance: Research Grade vs Oral Supplement Claims

| Feature | Research-Grade Injectable Peptides | Oral Peptide Supplements ||—|—|—|—|| Bioavailability | 85–95% (subcutaneous injection bypasses first-pass metabolism) | <5% (gastric acid and digestive enzymes degrade peptide bonds before absorption) || Mechani

This comparison does not assign a generated winner or score.

  • | Feature | Research-Grade Injectable Peptides | Oral Peptide Supplements ||—|—|—|—|| Bioavailability | 85–95% (subcutaneous injection bypasses first-pass metabolism) | <5% (gastric acid and digestive enzymes degrade peptide bonds before absorption) || Mechanism of Action | Direct receptor binding at physiological sites (bone marrow, pituitary, muscle tissue) | No demonstrated receptor binding; intact peptides do not cross intestinal barrier || Dosing Precision | Exact microgram dosing; repeatable blood plasma levels | Variable and unverified; no correlation between oral dose and systemic exposure || Evidence Quality | Randomised controlled trials with biomarker endpoints (VO₂ max, hematocrit, mitochondrial density) | Marketing claims without Phase 3 trial data; reliance on in vitro or animal studies || Regulatory Status | 503B compounding facilities under FDA oversight; batch testing for purity and potency | Dietary supplement (DSHEA); no premarket approval; batch-to-batch variability
  • The distinction matters for research design. Oral peptide supplements cannot replicate the receptor-binding effects of injectable peptides because peptide bonds are cleaved by pepsin in the stomach and pancreatic enzymes in the small intestine. Amino acids are absorbed, but the intact sequence. Which determines biological activity. Is destroyed. Studies claiming oral peptide bioavailability typically measure amino acid levels, not intact peptide structures.